ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded to "Strong-Buy" at Leerink Partnrs

Leerink Partnrs upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) to a strong-buy rating in a research report released on Wednesday morning,Zacks.com reports.

ANIP has been the subject of several other research reports. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday. They issued an "outperform" rating and a $80.00 price objective for the company. Piper Sandler began coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an "overweight" rating and a $68.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. StockNews.com downgraded ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Finally, Truist Financial raised their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research report on Tuesday, October 22nd. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $77.71.

ANI Pharmaceuticals Stock Down 3.0 %

ANIP stock traded down $1.80 during trading on Wednesday, hitting $57.37. 119,391 shares of the company's stock were exchanged, compared to its average volume of 220,707. The business has a 50-day moving average price of $58.04 and a two-hundred day moving average price of $60.39. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -107.58 and a beta of 0.73. ANI Pharmaceuticals has a 52-week low of $51.24 and a 52-week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same quarter in the previous year, the firm earned $1.05 EPS. The company's revenue was up 12.5% compared to the same quarter last year. As a group, equities research analysts expect that ANI Pharmaceuticals will post 3.87 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the company's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares in the company, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have sold 33,981 shares of company stock worth $1,970,066. 12.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Global Alpha Capital Management Ltd. boosted its holdings in ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock valued at $32,005,000 after purchasing an additional 9,500 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of ANI Pharmaceuticals in the second quarter valued at approximately $600,000. Susquehanna Fundamental Investments LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth $228,000. Thompson Siegel & Walmsley LLC raised its position in ANI Pharmaceuticals by 17.6% in the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock worth $13,731,000 after acquiring an additional 34,416 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in ANI Pharmaceuticals by 2.3% in the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock valued at $777,000 after acquiring an additional 299 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.